A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

被引：19
|
作者：
Cortes, Jorge E. [1 ]
Heidel, Florian H. [2 ,3 ]
Heuser, Michael [4 ]
Fiedler, Walter [5 ,6 ]
Smith, B. Douglas [7 ]
Robak, Tadeusz [8 ,9 ]
Fernandez, Pau Montesinos [10 ]
Ma, Weidong Wendy [11 ]
Shaik, M. Naveed [12 ]
Zeremski, Mirjana [12 ]
O'Connell, Ashleigh [13 ]
Chan, Geoffrey [13 ]
机构：
[1] Univ Texas M Anderson Canc Ctr, Houston, TX USA
[2] Otto Guericke Univ Med Ctr, Dept Hematol, Ctr Internal Med, Magdeburg, Germany
[3] Otto Guericke Univ Med Ctr, Dept Oncol, Ctr Internal Med, Magdeburg, Germany
[4] Hannover Med Sch, Hannover, Germany
[5] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Oncol, Hamburg, Germany
[6] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol, Hamburg, Germany
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Med Univ Lodz, Dept Hematol, Lodz, Poland
[9] Copernicus Mem Hosp, Lodz, Poland
[10] Hosp Univ Fe, Valencia, Spain
[11] Pfizer Oncol, New York, NY USA
[12] Pfizer Oncol, La Jolla, CA USA
[13] Pfizer Oncol, Collegeville, PA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.99.99
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
99
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Mylotarg, fludarabine, ara-C and cyclosporine (MFAC) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 339A - 339A
  • [22] EFFECT OF LOW-DOSE ARA-C TREATMENT AND THE COMBINATION TREATMENT WITH LOW-DOSE ARA-C AND HYDROXYVITAMIN-D3 IN ACUTE NONLYMPHOCYTIC LEUKEMIA AND MYELODYSPLASTIC SYNDROME
    SAWADA, H
    ABE, T
    TASHIMA, M
    YOSHIDA, Y
    YAMAGISHI, M
    OKUDA, T
    YUMOTO, Y
    KATO, Y
    UCHINO, H
    MYELODYSPLASTIC SYNDROMES : PATHOPHYSIOLOGY AND TREATMENT, 1988, 783 : 205 - 214
  • [23] Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.
    Heidel, F
    Cortes, J
    Ruecker, F
    Kaufmann, M
    Aulitzky, W
    Letvak, L
    Kindler, T
    Huber, C
    Dohner, H
    Kantarjian, H
    Fischer, T
    BLOOD, 2005, 106 (11) : 527A - 527A
  • [24] HIGH-DOSE ARA-C AND VP-16 WITH OR WITHOUT IDARUBICIN FOR INDUCTION OF REMISSION IN UNTREATED PRIMARY ACUTE MYELOID-LEUKEMIA
    MEHTA, J
    POWLES, R
    TRELEAVEN, J
    SINGHAL, S
    HORTON, C
    MILAN, S
    CATOVSKY, D
    BLOOD, 1994, 84 (10) : A145 - A145
  • [25] A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia
    Fukushima, Toshihiro
    Urasaki, Yoshimasa
    Yamaguchi, Masaki
    Ueda, Mikio
    Morinaga, Koji
    Haba, Toshihiro
    Sugiyama, Toshiro
    Nakao, Shinji
    Origasa, Hideki
    Umehara, Hisanori
    Ueda, Takanori
    ANTICANCER RESEARCH, 2012, 32 (02) : 643 - 647
  • [26] A phase 1b study of glasdegib plus azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Schuster, Michael
    Joris, Magalie
    Krauter, Juergen
    Maertens, Johan
    Breems, Dimitri
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ching, Keith
    O'Brien, Thomas
    Stampino, Corrado Gallo
    Ma, Weidong Wendy
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1689 - 1701
  • [27] A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse
    Kent, Andrew
    Vasu, Sumithira
    Schatz, Derek
    Monson, Natalie
    Devine, Steven
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    BLOOD, 2019, 134
  • [28] Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Yamauchi, Takahiro
    Negoro, Eiju
    Arai, Hajime
    Ikegaya, Satoshi
    Takagi, Kazutaka
    Takemura, Haruyuki
    Inai, Kunihiro
    Yoshida, Akira
    Urasaki, Yoshimasa
    Iwasaki, Hiromichi
    Ueda, Takanori
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2635 - 2639
  • [29] Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome
    Shadman, Mazyar
    Mawad, Raya
    Dean, Carol
    Chen, Tara L.
    Shannon-Dorcy, Kathleen
    Sandhu, Vicky
    Hendrie, Paul C.
    Scott, Bart L.
    Walter, Rol B.
    Becker, Pamela S.
    Pagel, John M.
    Estey, Elihu H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 483 - 486
  • [30] Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Shadman, Mazyar
    Mawad, Raya
    Dean, Carol
    Shannon-Dorcy, Kathleen
    Sandhu, Vicky
    Hendrie, Paul C.
    Scott, Bart L.
    Walter, Roland B.
    Becker, Pamela S.
    Pagel, John
    Estey, Elihu H.
    BLOOD, 2014, 124 (21)
12345